Aptose Biosciences Inc. (Aptose) is a clinical stage biotechnology company. The Company is engaged in development of targeted therapies addressing unmet medical needs in oncology. The Company has product candidates in two classes of anti-cancer therapies: Small molecule program and large molecule program. The Company's group of small molecule compounds includes lead drug APTO-253 in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies. APTO-253 is an inducer of the Kruppel-like factor 4 gene (the Klf4 Gene) for patients with advanced hematologic malignancies. Additionally, the Company has a preclinical small molecule program, APTO-500, targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of various cancers. The Company's large molecule program includes a molecule to target specific cell-surface receptors expressed in certain cancers expressing the Interleukin-17E receptor (IL-17ER).